{"disease":{"id":"barth-syndrome","name":"Barth syndrome","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"elamipretide","indication_name":"Barth syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Forzinity","generic_name":"ELAMIPRETIDE","company_name":"Stealth Biotheraps","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Forzinity works by binding to a specific site on mitochondria to improve their function."},{"drug_id":"elamipretide","indication_name":"Barth syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Forzinity","generic_name":"ELAMIPRETIDE","company_name":"Stealth Biotheraps","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Forzinity works by binding to a specific site on mitochondria to improve their function."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT07531251","title":"Ph3b/4 Trial in Patients With Barth Syndrome","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Stealth BioTherapeutics Inc.","has_results":false},{"nct_id":"NCT03098797","title":"A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Stealth BioTherapeutics Inc.","has_results":true},{"nct_id":"NCT04689360","title":"An Intermediate Size Expanded Access Protocol of Elamipretide","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Stealth BioTherapeutics Inc.","has_results":false},{"nct_id":"NCT01461304","title":"Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Jerry Vockley, MD, PhD","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}